SEVELAMER HYDROCHLORIDE tablet

Sevelamer hydrochloride by

Drug Labeling and Warnings

Sevelamer hydrochloride by is a Prescription medication manufactured, distributed, or labeled by Lupin Pharmaceuticals, Inc., LUPIN LIMITED. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Sevelamer hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The safety and efficacy of sevelamer hydrochloride tablets in CKD patients who are not on dialysis have not been studied.

  • 2 DOSAGE AND ADMINISTRATION

    Patients Not Taking a Phosphate Binder. The recommended starting dose of sevelamer hydrochloride tablets is 800 to 1600 mg, which can be administered as one or two 800 mg sevelamer hydrochloride tablets or two to four 400 mg sevelamer hydrochloride tablets, with meals based on serum phosphorus level.  Table 1 provides recommended starting doses of sevelamer hydrochloride for patients not taking a phosphate binder.

    Table 1: Starting Dose for Dialysis Patients Not Taking a Phosphate Binder
    Serum Phosphorus
    		Sevelamer  Hydrochloride Tablets 800 mg
    		Sevelamer  Hydrochloride Tablets 400 mg
    > 5.5 and < 7.5mg/dL
    		 1 tablet three times daily  with meals
    		 2 tablets three times daily  with meals
    ≥  7.5 and < 9.0 mg/dL
    		 2 tablets three times daily  with meals
    		 3 tablets three times daily  with meals
    ≥  9.0 mg/dL
    		 2 tablets three times daily  with meals
    		 4 tablets three times daily  with meals

    Patients Switching from Calcium Acetate. In a study in 84 CKD patients on hemodialysis, a similar reduction in serum phosphorus was seen with equivalent doses (approximately mg for mg) of sevelamer hydrochloride tablets and calcium acetate. Table 2 gives recommended starting doses of sevelamer hydrochloride tablets based on a patient's current calcium acetate dose.

    Table 2: Starting Dose for Dialysis Patients Switching From Calcium Acetate to Sevelamer Hydrochloride Tablets
    Calcium Acetate 667 mg
    (Tablets per meal)
    		Sevelamer  Hydrochloride  Tablets 800 mg
    (Tablets per meal)
    		SevelamerHydrochloride Tablets  400 mg 
    (Tablets per meal)
    1 tablet
    		 1 tablet
    		 2 tablets
    2 tablets
    		 2 tablets
    		 3 tablets
    3 tablets
    		 3 tablets
    		 5 tablets

    Dose Titration for All Patients Taking Sevelamer Hydrochloride Tablets. Adjust dosage based on the serum phosphorus concentration with a goal of lowering serum phosphorus to 5.5 mg/dL or less.  Increase or decrease by one tablet per meal at two-week intervals as necessary.  Table 3 gives a dose titration guideline.  The average dose in a Phase 3 trial designed to lower serum phosphorus to 5.0 mg/dL or less was approximately three sevelamer hydrochloride 800 mg tablets per meal.  The maximum average daily sevelamer hydrochloride dose studied was 13 g.

    Table 3: Dose Titration Guideline
    Serum Phosphorus
    		Sevelamer  Hydrochloride Tablets Dose
    >5.5 mg/dL
    		 Increase 1 tablet per meal at 2-week intervals
    3.5 to 5.5  mg/dL
    		 Maintain current dose
    <3.5 mg/dL
    		 Decrease 1 tablet per meal
  • 3 DOSAGE FORMS AND STRENGTHS

    Tablets:

    400 mg- White to off white, oval shaped biconvex film coated tablets imprinted with 'L024' in black ink on one side and plain on other side. 

    800 mg- White to off white, oval shaped biconvex film coated tablets imprinted with 'L025' in black ink on one side and plain on other side. 

  • 4 CONTRAINDICATIONS

    Sevelamer hydrochloride is contraindicated in patients with bowel obstruction.

    Sevelamer hydrochloride tablets are contraindicated in patients with known hypersensitivity to sevelamer hydrochloride or to any of the excipients.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Gastrointestinal Adverse Events

    Patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders, including severe constipation, or major GI tract surgery were not included in the sevelamer hydrochloride clinical studies.

    Dysphagia and esophageal tablet retention have been reported in association with use of sevelamer tablets, some requiring hospitalization and intervention. Consider using sevelamer suspension in patients with a history of swallowing disorders.

    Cases of bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have also been reported with sevelamer use. [see Adverse Reactions (6.2)]. Inflammatory disorders may resolve upon sevelamer hydrochloride discontinuation. Treatment with sevelamer hydrochloride should be re-evaluated in patients who develop severe gastrointestinal symptoms.

    5.2 Monitor Serum Chemistries

    Bicarbonate and chloride levels should be monitored.

    5.3 Monitor for Reduced Vitamins D, E, K (clotting factors) and Folic Acid Levels

    In preclinical studies in rats and dogs, sevelamer hydrochloride reduced vitamins D, E, and K (coagulation parameters) and folic acid levels at doses of 6 to 10 times the recommended human dose. In short-term clinical trials, there was no evidence of reduction in serum levels of vitamins. However, in a one-year clinical trial, 25-hydroxyvitamin D (normal range 10 to 55  ng/mL) fell from 39 ±  22 ng/mL to 34 ±  22 ng/mL (p < 0.01) with sevelamer  hydrochloride treatment.  Most (approximately 75%) patients in sevelamer hydrochloride clinical trials received vitamin supplements, which is typical of patients on dialysis.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    In a parallel design study of sevelamer hydrochloride with treatment duration of 52 weeks, adverse reactions reported for sevelamer hydrochloride (n=99) were similar to those reported for the active-control group (n=101). Overall adverse reactions among those treated with sevelamer hydrochloride occurring in > 5% of patients included:  vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%), and constipation (8%). A total of 27 patients treated with sevelamer and 10 patients treated with comparator withdrew from the study due to adverse reactions. 

    Based on studies of 8 to 52 weeks, the most common reason for withdrawal from sevelamer hydrochloride was gastrointestinal adverse reactions (3% to 16%).

     

    In 143 peritoneal dialysis patients studied for 12 weeks, most adverse reactions were similar to adverse reactions observed in hemodialysis patients. The most frequently occurring treatment-emergent serious adverse reaction was peritonitis (8 reactions in 8 patients [8%] in the sevelamer group and 2 reactions in 2 patients [4%] on active-control). Thirteen patients (14%) in the sevelamer group and 9 patients (20%) in the active-control group discontinued, mostly for gastrointestinal adverse reactions. Patients on peritoneal dialysis should be closely monitored to ensure the reliable use of appropriate aseptic technique with the prompt recognition and management of any signs and symptoms associated with peritonitis.

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during postapproval use of sevelamer hydrochloride: hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction and uncommon cases of ileus, intestinal obstruction, and intestinal perforation. Appropriate medical management should be given to patients who develop constipation or have worsening of existing constipation to avoid severe complications.

    Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.

  • 7 DRUG INTERACTIONS

    There are no empirical data on avoiding drug interactions between sevelamer hydrochloride and most concomitant oral drugs. For oral medication where a reduction in the bioavailability of that  medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [See Clinical Pharmacology (12.3)]. The duration of separation depends upon the absorption characteristics of the medication concomitantly administered, such as the time to reach peak systemic levels and whether the drug is an immediate-release or an extended-release product. Where possible monitor clinical responses or blood levels of concomitant drugs that have a narrow therapeutic range.  

    Table 4: Sevelamer Drug Interactions
    Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly
    Digoxin
    Enalapril
    Iron
    Metoprolol
    Warfarin
    Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer hydrochloride
    Ciprofloxacin
    Mycophenolate mofetil
    		 Dosing Recommendations
    Take at least 2 hours before or 6 hours after sevelamer
    Take at least 2 hours before sevelamer.
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Sevelamer hydrochloride is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug.

    Clinical Considerations

    Sevelamer hydrochloride may decrease serum levels of fat soluble vitamins and folic acid in pregnant women [See Clinical Pharmacology (12.2)]. Consider supplementing with these vitamins.

    Data

    Animal data:

    In pregnant rats given dietary doses of 0.5, 1.5, or 4.5 g/kg/day of sevelamer hydrochloride during organogenesis, reduced or irregular ossification of fetal bones, probably due to a reduced absorption of fat-soluble vitamin D, occurred at 7 to 21 times the maximum human equivalent dose of 13 g based on 60 kg body weight. In pregnant rabbits given oral doses of 100, 500, or 1000 mg/kg/day of sevelamer hydrochloride by gavage during organogenesis, an increase of early resorptions occurred in the high-dose group (human equivalent dose approximately 5 times the maximum clinical trial dose based on 60 kg body weight).

    8.2 Lactation

    Risk Summary

    Sevelamer hydrochloride is not absorbed systemically by the mother following oral administration and breastfeeding is not expected to result in exposure of the child to sevelamer hydrochloride.

    Clinical Considerations

    Sevelamer hydrochloride may decrease serum levels of fat soluble vitamins and folic acid in lactating women [See Clinical Pharmacology (12.2)]. Consider supplementing with these vitamins.

    8.4 Pediatric Use

    The safety and efficacy of sevelamer hydrochloride has not been established in pediatric patients.

    8.5 Geriatric Use

    Clinical studies of sevelamer hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

  • 10 OVERDOSAGE

    Sevelamer hydrochloride has been given to normal healthy volunteers in doses of up to 14 g per day for eight days with no adverse effects.  Sevelamer hydrochloride has been given in average doses up to 13 g per day to hemodialysis patients.  There are no reports of overdosage with sevelamer hydrochloride in patients.  Since sevelamer hydrochloride is not absorbed, the risk of systemic toxicity is low.

  • 11 DESCRIPTION

    The active ingredient in sevelamer hydrochloride tablets is sevelamer hydrochloride, a polymeric amine that binds phosphate and is meant for oral administration.  Sevelamer hydrochloride is poly (allylamine hydrochloride) crosslinked with epichlorohydrin in which 40 % of the amines are protonated.  It is known chemically as poly (allylamine-co-N, N'-diallyl-1,3-diamino-2-hydroxypropane) hydrochloride. Sevelamer hydrochloride is hydrophilic, but insoluble in water.  The structure is represented in Figure 1.

    Figure 1: Chemical Structure of Sevelamer Hydrochloride

    01

    The primary amine groups shown in the structure are derived directly from poly (allylamine hydrochloride).  The crosslinking groups consist of two secondary amine groups derived from poly (allylamine hydrochloride) and one molecule of epichlorohydrin.

    Sevelamer Hydrochloride Tablets:  Each film-coated tablet of sevelamer hydrochloride contains either 400 mg or 800 mg of sevelamer hydrochloride on an anhydrous basis.  The inactive ingredients are colloidal silicon dioxide, stearic acid and Opadry Clear 84F590009 containing polyethylene glycol, polyvinyl alcohol, and talc. The tablet imprint contains Opacode S-1-17823 Black containing ferrosoferric oxide, propylene glycol and shellac.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Sevelamer hydrochloride is a non-absorbed binding crosslinked polymer.  It contains multiple amines separated by one carbon from the polymer backbone.  These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding.  By binding phosphate in the dietary tract and decreasing absorption, sevelamer hydrochloride lowers the phosphate concentration in the serum.

    12.2 Pharmacodynamics

    In addition to effects on serum phosphate levels, sevelamer hydrochloride has been shown to bind bile acids in vitro and in vivo in experimental animal models.  Bile acid binding by ion exchange resins is a well-established method of lowering blood cholesterol. Because sevelamer binds bile acids, it may interfere with normal fat absorption and thus may reduce absorption of fat-soluble vitamins such as A, D, and K.  In clinical trials of sevelamer hydrochloride, both the mean total and LDL cholesterol declined by 15% to 31%.  This effect is observed after 2 weeks.  Triglycerides, HDL cholesterol, and albumin did not change.

    12.3 Pharmacokinetics

    A mass balance study using 14C-sevelamer hydrochloride in 16 healthy male and female volunteers showed that sevelamer hydrochloride is not systemically absorbed.  No absorption studies have been performed in patients with renal disease.

    Drug Interactions

    In vivo:

    Sevelamer carbonate has been studied in human drug-drug interaction studies (9.6 g once daily with a meal) with warfarin and digoxin. Sevelamer hydrochloride, which contains the same active moiety as sevelamer  carbonate, has been studied in human drug-drug interaction studies (2.4 to 2.8 g single dose or three times daily with meals or two times daily without meals) with ciprofloxacin, digoxin, enalapril, iron, metoprolol, mycophenolate mofetil and warfarin.

    Coadministered single dose of 2.8 g of sevelamer hydrochloride in fasted state decreased the bioavailability of ciprofloxacin by approximately 50% in healthy subjects. 

    Concomitant administration of sevelamer and mycophenolate mofetil in adult and pediatric patients decreased the mean MPA Cmax and AUC0-12h by 36% and 26%, respectively.

    Sevelamer carbonate or sevelamer hydrochloride did not alter the pharmacokinetics of a single dose of enalapril, digoxin, iron, metoprolol and warfarin when coadministered.

    During postmarketing experience, cases of increased thyroid stimulating hormone (TSH) levels have been reported in patients coadministered sevelamer hydrochloride and levothyroxine. Reduction in concentrations of cyclosporine and tacrolimus leading to dose increases has also been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (e.g., graft rejection). The possibility of an interaction cannot be excluded with these drugs.  

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Standard lifetime carcinogenicity bioassays were conducted in mice and rats. Rats were given sevelamer hydrochloride by diet at 0.3, 1, or 3 g/kg/day. There was an increased incidence of urinary bladder transitional cell papilloma in male rats of the high-dose group (human equivalent dose twice the maximum clinical trial dose of 13 g). Mice received dietary administration of sevelamer hydrochloride at doses of up to 9 g/kg/day (human equivalent dose 3 times the maximum clinical trial dose). There was no increased incidence of tumors observed in mice. 

    In an in vitro mammalian cytogenetic test with metabolic activation, sevelamer hydrochloride caused a statistically significant increase in the number of structural chromosome aberrations. Sevelamer hydrochloride was not mutagenic in the Ames bacterial mutation assay.

    Sevelamer hydrochloride did not impair the fertility of male or female rats in a dietary administration study in which the females were treated from 14 days prior to mating through gestation and the males were treated for 28 days prior to mating. The highest dose in this study was 4.5 g/kg/day (human equivalent dose 3 times the maximum clinical trial dose of 13 g).  

  • 14 CLINICAL STUDIES

    The ability of sevelamer hydrochloride to lower serum phosphorus in CKD patients on dialysis was demonstrated in six clinical trials:  one double-blind placebo-controlled 2-week study (sevelamer hydrochloride N=24); two open-label uncontrolled 8-week studies (sevelamer hydrochloride N=220) and three active-controlled open-label studies with treatment durations of 8 to 52 weeks (sevelamer hydrochloride N=256).  Three of the active controlled studies are described here.  One is a crossover study with two 8-week periods comparing sevelamer hydrochloride to an active-control. The second is a 52-week parallel study comparing sevelamer hydrochloride with active-control. The third is a 12-week parallel study comparing sevelamer hydrochloride and active-control in peritoneal dialysis patients.

    14.1 Active-Control, Cross-Over Study in Hemodialysis Patients

    Eighty-four CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus

     > 6.0 mg/dL) following a two-week phosphate-binder washout period received sevelamer hydrochloride and active control for eight weeks each in random order.  Treatment periods were separated by a two-week phosphate-binder washout period.  Patients started on treatment three times per day with meals.  Over each eight-week treatment period, at three separate time points the dose of sevelamer hydrochloride could be titrated up 1 capsule or tablet per meal (3 per day) to control serum phosphorus, the dose of active control could also be altered to attain phosphate control.  Both treatments significantly decreased mean serum phosphorus by about 2 mg/dL (Table 5).

    Table 5:Mean Serum Phosphorus (mg/dL) at Baseline and Endpoint
     
    		 Sevelamer Hydrochloride Tablets  (N=81)
    		Active-Control (N=83)
    Baseline at End of Washout
    		 8.4
    		 8.0
    Endpoint
    		 6.4
    		 5.9
    Change from Baseline at Endpoint
     (95% Confidence Interval)
    		 -2.0*
    (-2.5, -1.5)
    		 -2.1*
    (-2.6, -1.7)

    *p<0.0001, within treatment group comparison

     

    The distribution of responses is shown in Figure 2. The distributions are similar for sevelamer hydrochloride and active control. The median response is a reduction of about 2 mg/dL in both groups. About 50% of subjects have reductions between 1 and 3 mg/dL.

    Figure 2: Percentage of Patients (Y-axis) Attaining a Phosphorus Reduction from Baseline (mg/dL) at Least as Great as the Value of the X-axis

    02

    Average daily sevelamer hydrochloride dose at the end of treatment was 4.9 g (range of 0.0 to 12.6 g).

    14.2 Active-Control, Parallel Study in Hemodialysis Patients

    Two hundred CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus >5.5 mg/dL) following a two-week phosphate-binder washout period were randomized to receive sevelamer hydrochloride 800 mg tablets (N=99) or an active-control (N=101). The two treatments produced similar decreases in serum phosphorus. At week 52, using last observation carried forward, sevelamer hydrochloride and active control both significantly decreased mean serum phosphorus (Table 6).

    Table 6: Mean Serum Phosphorus (mg/dL) and Ion Product at Baseline and Change from Baseline to End of Treatment
     
    		 Sevelamer  Hydrochloride Tablets  (N=94)
    		Active-Control
     (N=98)
    Phosphorus
    Baseline
    Change from Baseline at Endpoint
    		 7.5
    -2.1
    		 7.3
    -1.8
    Ca x Phosphorus Ion Product
    Baseline
    Change from Baseline at Endpoint
    		 70.5
    -19.4
    		 68.4
    -14.2

    Sixty-one percent of sevelamer hydrochloride patients and 73% of the control patients completed the full 52 weeks of treatment. 

    Figure 3, a plot of the phosphorus change from baseline for the completers, illustrates the durability of response for patients who are able to remain on treatment.

    Figure 3. Mean Phosphorus Change from Baseline for Patients who Completed 52 Weeks of Treatment

    03

    Average daily sevelamer hydrochloride dose at the end of treatment was 6.5 g (range of 0.8 to 13 g). 

    14.3 Active-Control, Parallel Study in Peritoneal Dialysis Patients

    One hundred and forty-three patients on peritoneal dialysis, who were hyperphosphatemic (serum phosphorus > 5.5 mg/dL) following a two-week phosphate-binder washout period, were randomized to receive sevelamer  hydrochloride (N=97) or active control (N=46) open label for 12 weeks.  Average daily sevelamer hydrochloride dose at the end of treatment was 5.9 g (range 0.8 to 14.3 g). There were statistically significant changes in serum phosphorus (p < 0.001) for sevelamer hydrochloride (-1.6 mg/dL from baseline of 7.5 mg/dL), similar to the active control.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Sevelamer hydrochloride 800 mg tablets are supplied as white to off white, oval shaped biconvex film coated tablets imprinted with 'L025' in black ink on one side and plain on other side.  Sevelamer hydrochloride 800 mg Tablets are packaged in bottles of 180 tablets.

    Sevelamer hydrochloride 400 mg tablets are supplied as white to off white, oval shaped biconvex film coated tablets imprinted with 'L024' in black ink on one side and plain on other side.  Sevelamer hydrochloride 400 mg Tablets are packaged in bottles of 360 tablets.

    Bottle of 180 count 800 mg Tablets (NDC: 70748-173-26)   

    Bottle of 360 count 400 mg Tablets (NDC: 70748-172-27)   

    Storage: Store at 20° to 25°C (68° to 77°F):  excursions permitted to 15° to 30°C (59° to 86°F).   

    Do not use sevelamer hydrochloride tablets after the expiration date on the bottle.   

    [See USP controlled room temperature]   

    Protect from moisture. 

  • 17 PATIENT COUNSELING INFORMATION

    Advise patients to take sevelamer hydrochloride tablets with meals and adhere to their prescribed diets.

    Provide instructions on concomitant medications that should be dosed apart from sevelamer hydrochloride.

    Advise patients to report new onset or worsening of existing constipation or bloody stools promptly to their healthcare provider [see Warnings and Precautions (5.1)].

    Manufactured for:

    Lupin Pharmaceuticals, Inc.

    Baltimore, Maryland 21202

    United States.

    Manufactured by:

    Lupin Limited

    Nagpur- 441108,

    INDIA.

    Revised: July 2021                                                                                   ID#: 268129

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Sevelamer hydrochloride tablets, 400 mg

    NDC: 70748-172-27

    Bottle of 360's

    06

    Sevelamer hydrochloride tablets, 800 mg

    NDC: 70748-173-26

    Bottle of 180's

    07
  • INGREDIENTS AND APPEARANCE
    SEVELAMER HYDROCHLORIDE 
    sevelamer hydrochloride tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 70748-172
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SEVELAMER HYDROCHLORIDE (UNII: GLS2PGI8QG) (SEVELAMER - UNII:941N5DUU5C) SEVELAMER HYDROCHLORIDE400 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    STEARIC ACID (UNII: 4ELV7Z65AP)  
    POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)  
    TALC (UNII: 7SEV7J4R1U)  
    POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P)  
    POLYETHYLENE GLYCOL 6000 (UNII: 30IQX730WE)  
    SHELLAC (UNII: 46N107B71O)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    Product Characteristics
    ColorWHITE (off-white) Scoreno score
    ShapeOVAL (Biconvex) Size15mm
    FlavorImprint Code L024
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 70748-172-27360 in 1 BOTTLE; Type 0: Not a Combination Product02/25/2022
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21314502/25/2022
    SEVELAMER HYDROCHLORIDE 
    sevelamer hydrochloride tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 70748-173
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SEVELAMER HYDROCHLORIDE (UNII: GLS2PGI8QG) (SEVELAMER - UNII:941N5DUU5C) SEVELAMER HYDROCHLORIDE800 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    STEARIC ACID (UNII: 4ELV7Z65AP)  
    POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)  
    TALC (UNII: 7SEV7J4R1U)  
    POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P)  
    POLYETHYLENE GLYCOL 6000 (UNII: 30IQX730WE)  
    SHELLAC (UNII: 46N107B71O)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    Product Characteristics
    ColorWHITE (off-white) Scoreno score
    ShapeOVAL (Biconvex) Size19mm
    FlavorImprint Code L025
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 70748-173-26180 in 1 BOTTLE; Type 0: Not a Combination Product02/25/2022
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21314502/25/2022
    Labeler - Lupin Pharmaceuticals, Inc. (089153071)
    Registrant - LUPIN LIMITED (675923163)
    Establishment
    NameAddressID/FEIBusiness Operations
    LUPIN LIMITED650759348MANUFACTURE(70748-172, 70748-173) , PACK(70748-172, 70748-173)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.